MedTrace Logo

Radium-223 Dichloride Long-term Follow-up Program

NCT02312960 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2025-03-25

Study results available
· View outcomes & findings →

Summary

Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.

Conditions

  • Neoplasm Metastasis / Bone and Bones

Interventions

OTHER

Data Collection

No study treatment will be provided in this long term follow up study.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-18
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • Finland
  • France
  • Germany
  • Hong Kong
  • Israel
  • Italy
  • Japan
  • Norway
  • Poland
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312960 on ClinicalTrials.gov